Drug Profile
Trichostatin A - Vanda Pharmaceuticals
Alternative Names: VTR-297Latest Information Update: 02 Feb 2024
Price :
$50
*
At a glance
- Originator Vanda Pharmaceuticals
- Class Antibacterials; Antineoplastics; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Haematological malignancies
Most Recent Events
- 31 Jan 2024 US FDA approves IND application for Trichostatin A in Onychomycosis
- 31 Jan 2024 Vanda Pharmaceuticals plans a clinical trial for Onychomycosis (Topical)
- 10 Dec 2022 Adverse events data from a preclinical study in hematologic malignancies presented at the 64th American Society of Hematology Annual Meeting (ASH-2022)